Cytovance Biologics Revenue and Competitors

Location

$42.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cytovance Biologics's estimated annual revenue is currently $65.3M per year.(i)
  • Cytovance Biologics's estimated revenue per employee is $217,000
  • Cytovance Biologics's total funding is $42.5M.

Employee Data

  • Cytovance Biologics has 301 Employees.(i)
  • Cytovance Biologics grew their employee count by -3% last year.

Cytovance Biologics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Associate Director Analytical DevelopmentReveal Email/Phone
3
Director Business DevelopmentReveal Email/Phone
4
Sr. Director, Program ManagementReveal Email/Phone
5
Executive Director, Quality ControlReveal Email/Phone
6
Associate Director Microbial BioprocessReveal Email/Phone
7
Associate Director Quality AssuranceReveal Email/Phone
8
Associate Director Manufacturing (Upstream / Fill Finish)Reveal Email/Phone
9
Sr Director Research & DevelopmentReveal Email/Phone
10
Senior Director QualityReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.9M60%N/AN/A
#2
$0.8M50%N/AN/A
#3
$17.4M1123%N/AN/A
#4
$0.8M50%N/AN/A
#5
$65.3M301-3%$42.5MN/A
#6
$7.9M514%N/AN/A
#7
$2.8M180%N/AN/A
#8
$3.6M46-6%$14MN/A
#9
$1.4M90%N/AN/A
#10
$0.9M60%N/AN/A
Add Company

What Is Cytovance Biologics?

Our mission is to be the definitive full service contract manufacturer for the production of clinical scale therapeutic proteins and antibodies for the biotech industry. The Cytovance team understands from first-hand experience the need for more options for comprehensive contract manufacturing services. While there is some debate about the size of the cell culture capacity shortage for commercial stage biopharmaceutical products, the adequacy of clinical capacity is an equally critical question, especially for development stage companies. The clinical manufacturing capacity that does exist is mostly controlled by larger therapeutics companies or commercial scale contractors that are often inaccessible to development stage clients.

keywords:N/A

$42.5M

Total Funding

301

Number of Employees

$65.3M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cytovance Biologics News

2022-04-17 - Actionable Insights on Biologics Safety Testing Market by ...

Merck; SGS; WuXi AppTec; Thermo Fisher Scientific; Sartorius; Cytovance Biologics; Pace Analytical Services; Toxikon. Analysis of Cardan Shaft...

2022-04-17 - Biologics Safety Testing Market Size And Forecast | Charles ...

... Inc., Merck KGaA, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc., Wuxi Apptec, Sartorius AG, Cytovance Biologics, Inc.

2022-03-30 - Discovery-to-Clinic Path Smoothed by Open Source ...

McCool himself has 15 years of experience in the CDMO industry, having had technical and leadership roles at Lonza and Cytovance Biologics.

2021-08-23 - Production of Therapeutic Proteins in CHO cells, Integrated Mobile Clinical Services, Upcoming Webinar Hosted by Xtalks

Together, the Cytovance upstream and downstream platform processes meet a key need in the biologic industry to produce high quality product in conjunction with accelerated timelines and reduced costs on the path from cell line to clinical material. TORONTO (PRWEB) August 23, 2021 Despite the w ...

2014-10-28 - Cytovance Biologics Receives $20M Senior Credit Facility

Cytovance Biologics, Inc., Oklahoma City, Oklahoma-based contract manufacturing organization of mammalian and microbial biologics, received a $20m senior credit facility. Monroe Capital provided the financing. The company intends to use the funds to continue to grow operations. Cytovance work ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M3061%N/A
#2
$15M3097%N/A
#3
$85M309N/AN/A
#4
$94.9M310N/AN/A
#5
N/A31114%N/A